|
Extreme Liver Support™
The following Double Blind Studies have shown significant
decreases in degenerative liver damage in patients with chronic liver disease
(CIRRHOSIS of the LIVER) while using the same ingredients found in Extreme Health's Liver Support Formula in as few as 30 days. This is an extremely effective product for detoxifying the liver, normalizing liver metabolism and preventing further liver damage.
In the first Double Blind study, an extract of artichoke (Cynara Floridanum) and sarsaparilla (Smilax Aristolochiaefolia)
were evaluated in addressing the symptoms related to alcoholic liver disease. This 1st study was accomplished over a 15 day
period with exceptional results.
Because of these results noted over a very short period of time, the hospital researchers
were anxious to set up a 2nd
Double Blind Study over a longer period (30 day below).
(see results of 1st Study at bottom of webpage)
Diaz, A.; Hidalgo, L.; Noguez, F.;
*Maddrey, C.; Willis, Boitnott, K.; Bedine, S.; Weber, L.: Fredrick; Mezey, E.; White, R.; Corticosteriod Therapy
of Alcoholic Hepatitis. Gastroenterology 75: 193-199. 1978.
*Orrego, H.; Kalant, H.; Israel, Y.; Blake, J.; Medline, A.; Rankin, J.; Armstrong, A.; Kapur, B.; Effect of Short-
Term Therapy with Propylthiouracil in Patients with Alcoholic Liver Disease. Gastroenterology 76; 105-115. 1978.
In order to analyze carefully
the results of this study, it
is necessary to know the importance of the two clinical and
laboratory parameters intervening in the calculations of Orrego* and Maddrey Indexes*. We will compare the results
of the parameters, the placebo control and the Liver Support groups on both indexes. The results are presented
as
percentages of recovery and are obtained from the data obtained from each group of 30 patients; we will get an
average of those results at the beginning and at the end of the study. Both averages will give us a final recovery
compared to the initial values.
This way we may demonstrate the effectiveness of Extreme Liver Support.
COMPARATIVE STUDY BETWEEN A COMPLEX OF FLAVONOIDS
AND POLYPHENOLS CREATED FROM
EXTRACTS OF ARTICHOKE AND SARSAPARILLA AND A PLACEBO IN ALCOHOL RELATED LIVER DISEASE.
Results of this 30 Day study are as follows:
Parameters Tested
ASCITES - ENCEPHALOPATHY
- HEPATOMEGALY - SPLENOMEGALY
- WEAKNESS - PERIPHERAL EDEMA - HEMORRHAGES - ANOREXIA
ABDOMINAL WALL VEINS - PALMAR ERYTHEMA
- TELANGIECTASIA - TOTAL BILIRUBIN
- ALKALINE PHOSPHATASE
SERUM GLUTAMIC OXALCETIC TRANSAMINASE
(SGOT) - PROTHROMBIN TIME
SERUM ALBUMIN - GAMMA GLUTAMYL TRANSPEPTIDASE (GGT)
ASCITES
(accumulation of serous fluid in
the spaces between tissues
and organs in the cavity of the abdomen)
 |
A 72.38% reduction of the accumulation
of serous
abdominal fluid was noted in the treated group.
|
 |
The placebo group saw a 6.35% increase
in abdominal fluid.
|
ENCEPHALOPATHY
(a degenerative disease of the brain - a
condition usually occurring secondarily to advanced disease of the liver.
It is marked by disturbances of consciousness that may progress to deep coma (hepatic coma), psychiatric changes
of
varying degree, flapping tremor and fetor hepaticas. Also called portal-systemic encephalopathy.)
|
A 66.08% reduction of symptoms related to
encephalopathy was noted in the treated group.
|
|
The placebo group saw a 12.24% increase
in these symptoms.
|
HEPATOMEGALY
(enlargement of the liver)
|
The treated group experienced
a 93.33% reduction
in enlarged livers.
|
|
In the placebo group, their
livers
continued to enlarge by another
7.14%.
|
SPLENOMEGALY
(enlargement of the spleen)
|
An 88.40% reduction in spleen enlargement
was noted with the treated group.
|
|
The placebo group worsened by 11.54%.
|
WEAKNESS
(Lacking physical strength or vigor
marked by asthenia, atony,
cardiasthena, enervation, fatigue and lassitude.)
|
The treated group noted a 73.64% increase in strength.
|
|
There was a decrease in muscle strength by 7.41%
in the placebo group.
|
PERIPHERAL EDEMA
(A condition in which the body tissues
contain an excess amount of fluid.)
|
Edema in the extremities of
the treated patients
decreased by 48.21%.
|
|
There was no change in the placebo
group.
|
HEMORRHAGES
(Bleeding. This was one of the most
important benefits observed in the Liver Support group.)
|
The treated group noted a 100% decrease in capillary hemorrhaging
in the skin, gums, & nasal membranes.
|
|
The placebo group saw an increase of 28.57%
in hemorrhaging.
|
ANOREXIA
(Loss of appetite. Seen in depression,
malaise, commencement of fevers and illness,
also in disorders of the alimentary tract, especially of the stomach, and
as a result of alcoholic excess
and drug addiction.)
|
Loss of appetite decreased in
the treated group by 76.98%.
|
|
The placebo group noted a decrease
of 3.70%.
|
ABDOMINAL WALL VEINS
|
The treated group experienced
a 60.62% decrease in tortuous veins in the abdomen related to ascites
|
|
The placebo group saw a 3.33% decrease.
|
PALMAR ERYTHEMA
(an inflammatory redness of the
palms of the hands.)
|
The treated group noted a 26.67% decrease
in red and swollen palms.
|
|
In the placebo group there was
no change.
|
TELANGIECTASIA
(permanent dilation of preexisting
small blood vessels, creating focal red lesions.)
|
A 60.00% reduction in vascular lesions was
noted in the treated group.
|
|
A 3.33% reduction was seen in the placebo group.
|
TOTAL BILIRUBIN
(The predominant pigment of human
bile. Total serum bilirubin
may be increased in cirrhosis
of the liver and acute viral hepatitis.)
|
The treated group noted a reduction of
total bilirubin by 38.95%.
|
|
The placebo group increased by 5.68%.
|
ALKALINE PHOSPHATASE
(an enzyme that catalyzes the cleavage
of orthophosphate from orthophosphoric monoesters under
alkaline conditions. Differing forms of the enzyme occur in normal and malignant tissues.
The activity in serum is useful
in the clinical diagnosis of many illnesses.)
|
The treated group obtained 25.91% reduction
in alkaline phosphates.
|
|
There was an 11.69% increase in the placebo group.
|
SERUM GLUTAMIC OXALCETIC TRANSAMINASE
(SGOT)
(It is distributed all over body
tissue, especially in the heart and liver. Less amounts are found in the spleen,
pancreas, kidneys, lungs and brain. Any lesion of a tissue leads to the secretion of this enzyme to the blood stream.
The activity of SGOT is risen
under hepatic necrosis, cirrhosis of the liver or hepatic metastasis.)
|
The treated group noted a decrease of 23.83%
in SGOT levels.
|
|
The placebo group experienced
a worsening of 11.71%.
|
PROTHROMBIN TIME
(A test of clotting time made by
determining the time for clotting to occur after
thromboplastin and calcium are added to decalcified plasma.)
|
A 42.00% reduction in clotting time was
noted with the treated group.
|
|
A 6.60%increase
in clotting time was noted in the
placebo group.
|
SERUM ALBUMIN
(One of a group of simple proteins
widely distributed in tissues. Albumin is a constituent of blood.
Low levels of albumin in blood plasma are associated with a pathologic condition
of the liver.)
|
An increase of 37.27% in serum albumin
was noted in the treated group.
|
|
There was a decrease in the placebo group of 1.95%.
|
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT)
An enzyme that catalyzes the transfer
of a y-glutamyl group from glutathione or y-glutamyl peptide to
another peptide or amino acid; GGT is located on the cell membrane and microsomal fractions and is involved
in amino acid transport across cell membranes; GGT is highest in the liver–GGT is the best single screening assay for
detecting latent or chronic liver disease–eg,
CA; in hepatobiliary diseases, a 10-fold increase in GGT is seen in liver cancer,
hepatic metastases, and PBC; a 4-fold + increase in GGT is seen in chronic active hepatitis, intrahepatic cholestasis,
alcoholic hepatitis, extrahepatic biliary obstruction, and inactive cirrhosis.
|
The treated group noted a reduction of 23.79% in GGT.
|
|
The placebo group experienced an increase of 9.92%.
|
INTERPRETATION OF RESULTS OBTAINED
IN A DOUBLE BLIND TEST MADE WITH THE PRODUCT
LIVER SUPPORT ON PATIENTS HAVING CHRONIC ALCOHOLIC HEPATIC DISEASE.
DEFINTIONS AND RESULTS OF
PARAMETERS
ASCITES - Effusion and accumulation of serous fluid in the
abdominal cavity.
The experimental group (Liver
Support) experienced a 28.8% reduction of ascites while the placebo group experienced no change.
ENCEPHALOPATHY- a DEGENERATIVE
DISEASE OF THE BRAIN. Hepatic
encephalopathy- a condition usually occurring secondarily to advanced disease of the liver. It is marked by disturbances
of consciousness that may progress to deep coma (hepatic coma), psychiatric changes of varying degree, flapping
tremor and fetor hepaticas. Also called portal-systemic encephalopathy.
Patients on Liver Support experienced
a 34.55% reduction of hepatic encephalopathy.
The placebo group experienced a 5.5% reduction.
SPLENOMEGALIA - Enlargement of the spleen.
An 18.18% reduction was observed
in the Liver Support group and a 55% reduction was observed in the placebo group.
WEAKNESS- Lacking physical strength or vigor marked by asthenia,
atony, cardiasthena, enervation, fatigue and lassitude.
The Liver Support group experienced
an 83.45% decrease in the incidence of weakness
while the placebo group reported no change.
PERIPHERAL EDEMA - A condition in which the body tissues contain an
excess amount of fluid.
The Liver Support Group experienced
an 11.10% reduction in peripheral edema
while the placebo group had a 0.69% reduction.
HEMORRHAGES - Bleeding. This was one of the most important benefits
observed in the Liver Support group.
The Liver Support group had
an 89.41% reduction in hemorrhages
while the placebo had a 31% reduction.
ANOREXIA - Loss of appetite. Seen in depression, malaise, commencement
of fevers and illness, also in disorders of the alimentary tract, especially of the stomach, and as a result of
alcoholic excess and drug addiction.
Anorexia was diminished by
86.07% in the Liver Support group.
There was no change in the placebo group.
TOTAL BILIRUBIN LEVEL - The predominant pigment of human bile. Total serum
bilirubin may be increased in cirrhosis of the liver and acute viral hepatitis.
The Liver Support group obtained 25.11% reduction in bilirubin,
whereas the placebo group had a 7.2% increase.
SGOT - (SERUM GLUTAMIC OXALCETIC TRANSAMINASE). It is distributed all over body tissue, especially in the heart and liver. Less
amounts are found in the spleen, pancreas, kidneys, lungs and brain. Any lesion of a tissue leads to the secretion
of this enzyme to the blood stream. The activity of OGT is risen under hepatic necrosis, cirrhosis of the liver
or hepatic metastasis.
In those patients who received
Liver Support this level diminished 22.56% in only 15 days of treatment
and in the placebo group it diminished 8.51%.
PROTHROMBINE TIME - A test of clotting time made by determining the
time for clotting to occur after thromboplastin and calcium are added to decalcified plasma. This is very important
data, because it means that Liver Support helps the healing of wounds faster.
There was 30.82% reduction
in prothrombin time for Liver Support patients,
whereas the placebo group's time increased 1.25%.
SERUM ALBUMIN - One of a group
of simple proteins widely distributed in tissues. Albumin is a constituent of blood. Low levels of albumin in blood
plasma are associated with a pathologic condition of the liver.
The Liver Support group experienced
an increase of 8.85% of total albumin levels
while the placebo group experienced a 5.35% increase.
|
